Traws Pharma Net Worth
Traws Pharma Net Worth Breakdown | TRAW |
Traws Pharma Net Worth Analysis
Traws Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Traws Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Traws Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Traws Pharma's net worth analysis. One common approach is to calculate Traws Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Traws Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Traws Pharma's net worth. This approach calculates the present value of Traws Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Traws Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Traws Pharma's net worth. This involves comparing Traws Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Traws Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Traws Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Traws Pharma's net worth research are outlined below:
| Traws Pharma had very high historical volatility over the last 90 days | |
| Traws Pharma has a very high chance of going through financial distress in the upcoming years | |
| Traws Pharma was previously known as ONTX Old and was traded on NASDAQ Exchange under the symbol ONTX. | |
| The company reported the previous year's revenue of 226 K. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 226 K. | |
| Traws Pharma generates negative cash flow from operations | |
| Traws Pharma has a frail financial position based on the latest SEC disclosures | |
| About 26.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil |
Traws Pharma Target Price Consensus
Traws target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Traws Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Traws analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Traws stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Traws Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTraws Pharma Target Price Projection
Traws Pharma's current and average target prices are 2.57 and 6.50, respectively. The current price of Traws Pharma is the price at which Traws Pharma is currently trading. On the other hand, Traws Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Traws Pharma Target Price
Follow Traws Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.73 M.Market Cap |
|
Project Traws Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.75) | (0.79) | |
| Return On Capital Employed | (1.73) | (1.65) | |
| Return On Assets | (0.75) | (0.79) | |
| Return On Equity | (2.04) | (2.14) |
When accessing Traws Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Traws Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Traws Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Traws Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Traws Pharma. Check Traws Pharma's Beneish M Score to see the likelihood of Traws Pharma's management manipulating its earnings.
Evaluate Traws Pharma's management efficiency
Traws Pharma has return on total asset (ROA) of (0.8372) % which means that it has lost $0.8372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.5545) %, meaning that it created substantial loss on money invested by shareholders. Traws Pharma's management efficiency ratios could be used to measure how well Traws Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2025. Return On Capital Employed is likely to climb to -1.65 in 2025. At this time, Traws Pharma's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 2.2 M in 2025, whereas Non Currrent Assets Other are likely to drop 855.00 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.46 | 0.48 | |
| Tangible Book Value Per Share | 0.46 | 0.48 | |
| Enterprise Value Over EBITDA | (22.32) | (23.44) | |
| Price Book Value Ratio | 34.96 | 30.16 | |
| Enterprise Value Multiple | (22.32) | (23.44) | |
| Price Fair Value | 34.96 | 30.16 | |
| Enterprise Value | 354.3 M | 412.8 M |
Evaluating the management effectiveness of Traws Pharma allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Traws Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Traws Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Traws Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Traws Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Traws Pharma time-series forecasting models is one of many Traws Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Traws Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Traws Pharma Earnings per Share Projection vs Actual
Traws Pharma Corporate Management
| Robert MD | Acting Officer | Profile | |
| Mark CPA | Chief Officer | Profile | |
| Victor MD | Chief Oncology | Profile | |
| Nora Brennan | Interim Officer | Profile |
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.